Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbohydrate-electrolyte solution plus dexmedetomidine for prevention of postoperative nausea and vomiting
ChiCTR2600131966Phase 4Not yet recruiting
- Sponsor
- Zigong Fourth People's Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in postoperative nausea and vomiting (PONV) (4 arms), sponsored by Zigong Fourth People's Hospital. Primary endpoint: Postoperative nausea and vomiting. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2600131966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131966.